Name: UMIN ID:
Unique ID issued by UMIN | UMIN000016553 |
---|---|
Receipt number | R000019185 |
Scientific Title | Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics. |
Date of disclosure of the study information | 2015/02/28 |
Last modified on | 2023/01/17 08:37:23 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/02/16 19:29:14 | ||
2 | Update | 2015/04/02 18:03:32 | Recruitment status |
|
3 | Update | 2015/04/17 15:05:26 | Other related information |
|
4 | Update | 2015/04/17 15:10:17 | Key inclusion criteria Key inclusion criteria |
|
5 | Update | 2016/02/22 15:41:12 | Key exclusion criteria Key exclusion criteria |
|
6 | Update | 2016/02/22 16:06:54 | Other related information |
|
7 | Update | 2016/02/22 16:19:19 | Other related information Other related information |
|
8 | Update | 2017/02/16 12:29:45 | Recruitment status |
|
9 | Update | 2017/08/18 13:53:39 | Name of primary person or sponsor Organization Organization |
|
10 | Update | 2017/08/18 13:57:29 | Other related information |
|
11 | Update | 2019/02/19 13:11:16 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
12 | Update | 2019/08/20 12:26:00 | Number of participants that the trial has enrolled |
|
13 | Update | 2020/08/20 09:32:41 | Recruitment status Date of IRB |
|
14 | Update | 2020/08/20 09:38:34 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
15 | Update | 2020/08/20 10:34:58 | Recruitment status |
|
16 | Update | 2022/12/07 10:35:10 | Recruitment status |
|
17 | Update | 2022/12/07 10:47:50 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
18 | Update | 2022/12/07 10:52:42 | Anticipated trial start date Last follow-up date |
|
19 | Update | 2023/01/16 14:34:03 | Outcome measures |
|
20 | Update | 2023/01/17 08:19:29 | Results Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Adverse events Outcome measures |
|
21 | Update | 2023/01/17 08:37:23 | Institutions |